Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from
The Department of Health and Human Services has awarded Gaithersburg, Md.-based biopharmaceutical company Emergent BioSolutions a $628M task order to…
Emergent BioSolutions (NYSE: EBS) has received a potential 10-year, $535M contract to supply the Department of Health and Human Services…
Emergent BioSolutions (NYSE: EBS)Â has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the
The Biomedical Advanced Research and Development Authority has awarded Emergent BioSolutions (NYSE: EBS)Â a potential $21.9 million task order to develop
The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31
The U.S. government has selected Emergent BioSolutions Inc. (NYSE: EBS) to supply millions of doses of its anthrax vaccine over five
